Bellicum Reports First Quarter 2016 Financial Results

HOUSTON--(BUSINESS WIRE)--Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for cancers and orphan inherited blood disorders, today reported financial results for the first quarter of 2016 and provided an update on recent developments.

Back to news